TIAA CREF Investment Management LLC purchased a new position in shares of Ovid Therapeutc (NASDAQ:OVID) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 13,561 shares of the company’s stock, valued at approximately $142,000. TIAA CREF Investment Management LLC owned about 0.06% of Ovid Therapeutc at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Bank of New York Mellon Corp purchased a new position in shares of Ovid Therapeutc during the 2nd quarter valued at approximately $135,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Ovid Therapeutc during the 2nd quarter valued at approximately $153,000. Alps Advisors Inc. purchased a new position in shares of Ovid Therapeutc during the 2nd quarter valued at approximately $233,000. Victory Capital Management Inc. purchased a new position in shares of Ovid Therapeutc during the 2nd quarter valued at approximately $1,374,000. Finally, Sphera Funds Management LTD. purchased a new position in shares of Ovid Therapeutc during the 2nd quarter valued at approximately $3,042,000. 31.20% of the stock is owned by institutional investors.

Shares of Ovid Therapeutc (NASDAQ:OVID) opened at $10.72 on Friday. Ovid Therapeutc has a one year low of $5.28 and a one year high of $15.93.

Ovid Therapeutc (NASDAQ:OVID) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.16. sell-side analysts expect that Ovid Therapeutc will post -4.08 earnings per share for the current fiscal year.

Separately, Zacks Investment Research raised shares of Ovid Therapeutc from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Thursday, November 16th. Five equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $19.33.

COPYRIGHT VIOLATION WARNING: This story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/11/25/tiaa-cref-investment-management-llc-purchases-new-stake-in-ovid-therapeutc-ovid.html.

Ovid Therapeutc Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Want to see what other hedge funds are holding OVID? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ovid Therapeutc (NASDAQ:OVID).

Institutional Ownership by Quarter for Ovid Therapeutc (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.